Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Phase I Study
100%
Chimeric Protein
100%
Receptor Expression
100%
Mycosis Fungoides
100%
Soluble interleukin-2 Receptor (sIL-2R)
100%
Fusion Toxin
100%
Sézary Syndrome
100%
Stable Disease
83%
Progressive Disease
50%
Diphtheria Toxin
50%
CD25
33%
Cutaneous T-cell Lymphoma
33%
Clinical Response
16%
Quantitative PCR
16%
Ligand-binding Domain
16%
Serum Concentration
16%
In(III)
16%
Interleukin-2
16%
Response Predictors
16%
Complete Response
16%
Partial Response
16%
Antibody Titer
16%
Short Half-life
16%
Biologic Effect
16%
US Government
16%
Hepatic Transaminases
16%
Cell Surface Binding
16%
Area under the Concentration Curve
16%
Circulating Neoplastic Cells
16%
Recombinant Toxin
16%
Government Work
16%
Repeated Courses
16%
Medicine and Dentistry
Receptor Expression
100%
Mycosis fungoides
100%
Interleukin 2 Receptor
100%
Chimeric Protein
100%
Sezary Syndrome
100%
Diseases
100%
Interleukin 2
80%
Receptor
60%
Progressive Disease
60%
Infusion
40%
Cutaneous T Cell Lymphoma
40%
Diphtheria
40%
Toxin Antibody
40%
Cell Surface
20%
Transaminase
20%
Diphtheria Toxin
20%
Tumor Embolism
20%
Reverse Transcription Polymerase Chain Reaction
20%
Biological Activity
20%
Neuroscience
Receptor Expression
100%
Interleukin 2
100%
Chimeric Protein
100%
Interleukin 2 Receptor
100%
Mycosis
100%
Diphtheria
75%
Receptor
75%
T Cell
50%
Toxin Antibody
50%
Transaminase
25%
Reverse Transcription Polymerase Chain Reaction
25%
Immunology and Microbiology
Interleukin 2
100%
Interleukin 2 Receptor
100%
T Cell
50%
Toxin Antibody
50%
CD25
50%
Cell Surface
25%
Antibody Titer
25%
Maximum Plasma Concentration
25%
Reverse Transcription Polymerase Chain Reaction
25%
Biological Activity
25%
Veterinary Science and Veterinary Medicine
Mycosis Fungoides
100%
Diseases
100%
Diphtheria
37%
Cutaneous T-Cell Lymphoma
25%
Reverse Transcription Polymerase Chain Reaction
12%
Neoplastic Cell
12%